Biocon Ltd’s fundamental analysis reveals key financial metrics: Market Cap of ₹40,754.51 crore, PE Ratio of 39.86, Debt to Equity of 64.4 and Return on Equity of 4.28%. These indicators offer insights into the company’s financial health and market valuation.
Content:
Biocon Ltd Overview
Biocon Ltd is an Indian biopharmaceutical company focusing on treating diabetes, cancer and autoimmune diseases. It operates in the pharmaceutical sector, with segments including Generics, Biosimilars, Novel Biologics, and Research Services.
The company is listed on both the NSE and BSE. With a market capitalization of ₹40,754.51 crore, it’s currently 10.69% away from its 52-week high and 56.51% away from its 52-week low.
Biocon Financial Results
Biocon Ltd demonstrated solid growth in FY 24, with sales rising from ₹11,174 crore in FY 23 to ₹14,756 crore. The company also improved its profitability, showcasing a strong financial position with a growing asset base.
1. Revenue Trend: Sales increased by ₹3,582 crore, from ₹11,174 crore in FY 23 to ₹14,756 crore in FY 24, reflecting a robust growth trajectory.
2. Equity and Liabilities: Equity capital remained at ₹600.30 crore, while total liabilities increased by ₹4,028 crore to ₹56,071 crore in FY 24, indicating expanding financial commitments.
3. Profitability: Operating profit rose from ₹2,512 crore in FY 23 to ₹3,299 crore in FY 24, with a consistent OPM of 22%.
4. Earnings per Share (EPS): EPS more than doubled, increasing from ₹3.88 in FY 23 to ₹8.55 in FY 24, highlighting improved earnings per share.
5. Return on Net Worth (RoNW): RoNW improved significantly due to the rise in net profit, reflecting better utilization of shareholders’ equity.
6. Financial Position: Total assets grew by ₹4,028 crore to ₹56,071 crore in FY 24, showcasing a strong financial base and a well-managed balance sheet.
Biocon Ltd Financial Analysis
| FY 24 | FY 23 | FY 22 | |
| Sales | 14,756 | 11,174 | 8,184 |
| Expenses | 11,457 | 8,663 | 6,214 |
| Operating Profit | 3,299 | 2,512 | 1,970 |
| OPM % | 22 | 22 | 24 |
| Other Income | 854 | 85 | 102 |
| EBITDA | 4,164 | 2,888 | 2,183 |
| Interest | 974 | 419 | 68 |
| Depreciation | 1,569 | 1,113 | 814 |
| Profit Before Tax | 1,609 | 1,064 | 1,190 |
| Tax % | 14 | 24 | 18 |
| Net Profit | 1,298 | 643 | 772 |
| EPS | 8.55 | 3.88 | 5.44 |
| Dividend Payout % | 5.85 | 38.66 | 9.19 |
* Consolidated Figures in Rs. Crores
Biocon Ltd Company Metrics
Biocon Ltd’s company metrics include a market capitalization of ₹40,754.51 crore, a book value per share of ₹165, and a face value of ₹5. With a debt-to-equity ratio of 64.4, a return on equity of 4.28%, and a 0.15% dividend yield, these figures underscore the company’s financial position and investment profile.
Market Capitalization: Market Capitalization represents the total market value of Biocon’s outstanding shares, amounting to ₹40,754.51 crore.
Book Value: The book value per share of Biocon Ltd is ₹165 indicating the value of the company’s net assets divided by its shares outstanding.
Face Value: The face value of Biocon’s shares is ₹5, which is the original cost of the shares as stated on the certificate.
Asset Turnover Ratio: The asset turnover ratio of 0.29 measures how efficiently Biocon uses its assets to generate revenue.
Total Debt: The total debt of ₹16,276.7 crore represents the sum of all short-term and long-term debt obligations of Biocon.
Return on Equity (ROE): The ROE of 4.28% measures Biocon’s profitability in generating income from its equity investments.
EBITDA (Q): The quarterly EBITDA of ₹953 crore represents Biocon’s earnings before interest, taxes, depreciation, and amortization.
Dividend Yield: The dividend yield of 0.15% shows the annual dividend payment as a percentage of Biocon’s current share price, indicating the return on investment from dividends alone.
Biocon Ltd Stock Performance
Biocon Ltd has achieved a 1-year return on investment of 32.4%, a 3-year return of -3.18%, and a 5-year return of 8.13%. These returns illustrate the company’s performance over various investment periods, showing significant short-term growth but moderate long-term performance.
| Period | Return on Investment (%) |
| 1 Year | 32.4 |
| 3 Years | -3.18 |
| 5 Years | 8.13 |
Example: If an investor had invested ₹1,000 in the stock:
1 year ago, their investment would be worth ₹1,324.
3 years ago, their investment would have decreased to approximately ₹968.20.
5 years ago, their investment would have grown to approximately ₹1,081.30.
Biocon Ltd Peer Comparison
Biocon Ltd, with a CMP of ₹326 and a market cap of ₹39,164 crore, shows moderate performance with a 1-year return of 32%. It lags behind peers like Sun Pharma and Aurobindo Pharma, which achieved 1-year returns of 53% and 73%, respectively.
| Name | CMP Rs. | Mar Cap Rs.Cr. | P/E | ROE % | EPS 12M Rs. | 1Yr return % | ROCE % | Div Yld % |
| Sun Pharma.Inds. | 1,738 | 4,17,004 | 40 | 17 | 43 | 53 | 17 | 0.77 |
| Cipla | 1,574 | 1,27,133 | 29 | 17 | 53 | 28 | 23 | 0.82 |
| Zydus Lifesci. | 1,157 | 1,16,457 | 28 | 21 | 42 | 83 | 22.34 | 0.25 |
| Dr Reddy’s Labs | 6,885 | 1,14,862 | 21 | 21 | 334 | 19.32 | 26.53 | 0.57 |
| Lupin | 2,075 | 94,612 | 42 | 14 | 50 | 94 | 16 | 0.39 |
| Mankind Pharma | 2,211 | 88,576 | 47 | 20 | 48 | 20 | 24.57 | – |
| Aurobindo Pharma | 1,478 | 86,584 | 24 | 12 | 60 | 73 | 14.1 | 0.30 |
| Biocon | 326 | 39,164 | 40 | 5 | 13 | 32 | 6 | 0.15 |
Biocon Shareholding Pattern
Biocon Ltd’s shareholding pattern as of June 2024 shows promoters holding steady at 60.64%. Foreign Institutional Investors (FII) hold 5.9%, slightly up from March. Domestic Institutional Investors (DII) have 14.29%, while retail and others account for 19.18%, reflecting diverse investor interest.
| All values in % | Jun-24 | Mar-24 | 45,261 |
| Promoters | 60.64 | 60.64 | 60.64 |
| FII | 5.9 | 5.63 | 6.55 |
| DII | 14.29 | 13.69 | 14.51 |
| Retail & others | 19.18 | 20.06 | 18 |
Biocon History
Biocon Limited is an India-based biopharmaceutical company specializing in treatments for diabetes, cancer and autoimmune diseases. It operates across four key segments: Generics, Biosimilars, Novel Biologics and Research Services, demonstrating its diverse approach to pharmaceutical development and production.
The company has successfully developed and commercialized novel biologics, biosimilars and complex small-molecule active pharmaceutical ingredients (APIs) in India and several global markets. Biocon’s product portfolio extends to Generic Formulations, which it markets in the United States, Europe and key emerging markets.
Biocon’s API portfolio includes products for cardiology, anti-diabetics, immunosuppressants, multiple sclerosis and oncology. With five facilities across Bangalore, Hyderabad and Visakhapatnam in India, the company leverages complex technology platforms for manufacturing, including microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
How To Invest In Biocon Ltd Share?
To invest in Biocon shares, open a demat account with Alice Blue. Research the company’s fundamentals, financial performance, and position in the biopharmaceutical industry. Analyze historical stock data and compare it with industry peers.
Determine your investment strategy based on your financial goals and risk tolerance. Consider factors such as the company’s drug pipeline, regulatory approvals, and global market expansion plans. Decide on the investment amount and timing.
Place your order through the broker’s platform. Regularly monitor your investment, staying updated on company news, quarterly results, and pharmaceutical industry trends. Consider seeking advice from a financial advisor for personalized guidance and to ensure your investment aligns with your overall portfolio strategy.
Biocon Limited Fundamental Analysis – FAQs
Biocon Ltd’s fundamental analysis reveals a Market Cap of ₹40,754.51 crore, PE Ratio of 39.86, Debt to Equity of 64.4, and Return on Equity of 4.28%. These metrics provide insights into the company’s financial health, profitability, and market valuation.
Biocon Ltd’s market capitalization is ₹40,754.51 crore. This figure represents the total value of the company’s outstanding shares in the stock market, calculated by multiplying the current stock price by the number of outstanding shares.
Biocon Limited is an Indian biopharmaceutical company specializing in treatments for diabetes, cancer, and autoimmune diseases. It operates in four key segments: Generics, Biosimilars, Novel Biologics, and Research Services, developing and commercializing a wide range of pharmaceutical products globally.
Biocon is a public limited company, with Kiran Mazumdar-Shaw as its founder and executive chairperson. While she holds a significant stake, the company’s ownership is distributed among various institutional and public shareholders as it is listed on stock exchanges.
The main shareholders of Biocon Ltd include the promoter group led by Kiran Mazumdar-Shaw, along with institutional investors and public shareholders. For the most current and accurate information on major shareholders, refer to the company’s latest shareholding pattern disclosure.
Biocon operates in the biopharmaceutical industry. The company focuses on developing and manufacturing a wide range of pharmaceutical products, including biosimilars, generics, novel biologics, and active pharmaceutical ingredients (APIs), primarily for diabetes, oncology, and autoimmune diseases.
To invest in Biocon shares, open a demat account with Alice Blue. Research the company’s performance and industry trends. Decide on your investment strategy. Place your order through the broker’s platform. Regularly monitor your investment, staying informed about market conditions. Consider seeking financial advice for personalized guidance.
To invest in Bharat Heavy Electricals shares, open a demat account with Alice Blue. Research the company’s performance and sector trends. Decide on your investment strategy. Place your order through the broker’s platform. Regularly monitor your investment, staying informed about market conditions. Consider seeking financial advice for personalized guidance.
